At the same time, analyst Richard Vosser raised the target price of the diabetes specialist’s stock from 925 to 1100 Danish crowns and confirmed his “overweight” rating in the study published on Tuesday. Vosser advises sticking with quality stocks. He reduced his 2023 estimates only slightly for the sector, as it is likely to retain its high premium at least during recession concerns. He also sees a dichotomy in the prospects of the pharmaceutical companies in the new year in terms of short-term forecasts and pipelines, as well as in the longer term up to 2030. Novo Nordisk shines with consistently higher growth and a good pipeline. The stock is one of his “top picks”.
On the Copenhagen stock exchange, Novo Nordisk shares temporarily rose by 2.73 percent to 967.70 Danish kroner.
/ck/la
Publication of the original study: 30.12.2022 / 21:34 / GMT
First distribution of the original study: 03.01.2023 / 00:15 / GMT
NEW YORK (dpa-AFX Broker)
Leverage must be between 2 and 20
No data
More news about Novo Nordisk
Image sources: Novo Nordisk